StreetInsider.com News Articles

Form 8-K ALX ONCOLOGY HOLDINGS For: Jun 10

Thu, 11 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260611/26635527.html

Form 8-K ALX ONCOLOGY HOLDINGS For: Jun 10

Thu, 11 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260611/26635527.html

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

Mon, 01 Jun 2026 08:00:00 -0400

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in a fireside chat presentation at the 2026 Jefferies Global Healthcare Conference in New York.

The details of the meeting are as follows:

2026 Jefferies Global Healthcare Conference in New York

Format: Fireside Chat Presentation
Date: June 3, 2026
Time: 5:30 PM ET
Webcast link: Available here

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

Mon, 01 Jun 2026 08:00:00 -0400

The details of the meeting are as follows:

2026 Jefferies Global Healthcare Conference in New York

Format: Fireside Chat Presentation
Date: June 3, 2026
Time: 5:30 PM ET
Webcast link: Available here

Form SCHEDULE 13D/A ALX ONCOLOGY HOLDINGS Filed by: LSV Associates, LLC

Wed, 27 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260527/26558146.html

Form SCHEDULE 13D/A ALX ONCOLOGY HOLDINGS Filed by: LSV Associates, LLC

Wed, 27 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260527/26558146.html

Form SCHEDULE 13G/A ALX ONCOLOGY HOLDINGS Filed by: Redmile Group, LLC

Fri, 15 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260515/26505937.html

Form SCHEDULE 13G/A ALX ONCOLOGY HOLDINGS Filed by: Redmile Group, LLC

Fri, 15 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260515/26505937.html

Form SCHEDULE 13G/A ALX ONCOLOGY HOLDINGS Filed by: HBM Healthcare Investments (Cayman) Ltd.

Fri, 15 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260515/26505191.html

Form SCHEDULE 13G/A ALX ONCOLOGY HOLDINGS Filed by: HBM Healthcare Investments (Cayman) Ltd.

Fri, 15 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260515/26505191.html

ALX Oncology Holdings Inc. (ALXO) Tops Q1 EPS by 2c

Fri, 08 May 2026 08:12:40 -0400

ALX Oncology Holdings Inc. (NASDAQ: ALXO) reported Q1 EPS of ($0.17), $0.02 better than the analyst estimate of ($0.19).

For earnings history and earnings-related data on ALX Oncology Holdings Inc. (ALXO) click here.

Form 10-Q ALX ONCOLOGY HOLDINGS For: Mar 31

Fri, 08 May 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260508/26458130.html

Form 10-Q ALX ONCOLOGY HOLDINGS For: Mar 31

Fri, 08 May 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260508/26458130.html

Form 8-K ALX ONCOLOGY HOLDINGS For: May 08

Fri, 08 May 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260508/26458048.html

Form 8-K ALX ONCOLOGY HOLDINGS For: May 08

Fri, 08 May 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260508/26458048.html

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 08 May 2026 08:00:00 -0400

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -

- Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer -

- Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 -

- Phase 1 trial evaluating ALX2004 continues to enroll

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 08 May 2026 08:00:00 -0400

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -

- Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer -

- Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 -

- Phase 1 trial evaluating ALX2004 continues to enroll

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 08 May 2026 08:00:00 -0400

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -

- Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer -

- Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 -

- Phase 1 trial evaluating ALX2004 continues to enroll

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 08 May 2026 08:00:00 -0400

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -

- Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer -

- Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 -

- Phase 1 trial evaluating ALX2004 continues to enroll

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 08 May 2026 08:00:00 -0400

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -

- Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer -

- Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 -

- Phase 1 trial evaluating ALX2004 continues to enroll

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 08 May 2026 08:00:00 -0400

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -

- Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer -

- Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 -

- Phase 1 trial evaluating ALX2004 continues to enroll

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 08 May 2026 08:00:00 -0400

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -

- Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer -

- Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 -

- Phase 1 trial evaluating ALX2004 continues to enroll

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 08 May 2026 08:00:00 -0400

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -

- Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer -

- Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 -

- Phase 1 trial evaluating ALX2004 continues to enroll

ALX Oncology reports positive trial results in breast cancer treatment

Thu, 07 May 2026 08:01:57 -0400

ALX Oncology Holdings Inc. (NASDAQ: ALXO) reported trial data showing its investigational drug evorpacept combined with zanidatamab produced responses in patients with advanced HER2-positive breast cancer who had high CD47 expression levels.
The Phase 1b/2 trial data, presented at the ESMO Breast Cancer 2026 congress, showed patients with centrally confirmed HER2-positive metastatic breast cancer and high CD47 expression achieved a 100% confirmed objective response rate. This compared to a 25% response rate in patients with lower CD47 expression levels.
Patients with high CD47 expression had a median progression-free survival of 22.1 months versus 3.4 months for those with low expression. The median

ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

Thu, 07 May 2026 08:00:00 -0400

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -

- Findings are consistent with previous results from the randomized ASPEN-06 trial in HER2-positive gastric cancer, which indicated CD47 expression could potentially serve as an important predictive biomarker of evorpacept activity -

- ALX Oncology will host a webcast on May 8 to report first quarter 2026 financial results; breast cancer expert will discuss the evorpacept + zanidatamab trial results in detail -

SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE